Tempus AI Q2 revenue slightly beats estimates
Tempus AI Q2 revenue slightly beats estimates
Overview
US precision medicine AI firm's Q2 revenue rose 22% yr/yr, slightly beating analyst expectations
Adjusted EBITDA missed estimates
Company raised 2026 revenue guidance
Outlook
Tempus raises 2026 revenue guidance to $1.595-$1.605 bln
Company continues to expect 2026 adjusted EBITDA of ~$65 mln
Guidance excludes impact from Personalis acquisition, expected to close late Q4 2026 or early 2027
Result Drivers
ONCOLOGY DIAGNOSTICS GROWTH - Co said 31% yr/yr growth in oncology test volume drove diagnostics revenue, with MRD test volume also rising
DATA LICENSING DEALS - Co attributed 36% yr/yr growth in Insights revenue and ~$200 mln in new Data and Applications licenses to large deals with pharma clients
PRODUCT APPROVALS AND LAUNCHES - Co cited FDA approval of xT Tumor Only assay and launch of Tempus Preview as operational highlights supporting business momentum
Company press release: ID:nBwgr9wla
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Slight Beat* | $382.49 mln | $379.74 mln (16 Analysts) |
Q2 Adjusted Loss Per Share | Beat | $0.04 | $0.14 (12 Analysts) |
Q2 Net Income |
| $5.64 mln |
|
Q2 Adjusted EBITDA | Miss | $8.04 mln | $8.49 mln (11 Analysts) |
Q2 Income from Operations |
| -$75.91 mln |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 7 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Tempus AI Inc is $67.00, about 61.3% above its July 29 closing price of $41.55
Reuters Recommended Reads
July 28 - NeoGenomics Q2 revenue beats estimates, raises outlook
July 29 - Adaptive Biotechnologies Q2 revenue rises 22%, beats estimates
July 30 - Labcorp Q2 revenue slightly beats estimates, lifts 2026 outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Tempus AI
See all newsU.S. STOCKS ON THE MOVE-Tempus AI, Choice Hotels, Palantir
Tempus AI rises after surprise quarterly profit
Tempus AI Q3 revenue slightly beats estimates; raises guidance
Brief: Tempus Receives Ivdr Certification For Xr Rna Sequencing For Solid Tumor Profiling
Brief: Tempus Expands Strategic Collaboration With Bristol Myers Squibb